Birkett RT, Chamely E, Concors SJ, et al. - Using the National Cancer Database, researchers examined the use and effectiveness of adjuvant chemotherapy (aCTX) in patients with both normal-risk (NR) and high-risk (HR) young stage II colon cancer. Between 2010 and 2015, patients with stage II colon cancer who had colectomy were identified. HR individuals involved at least: lymphovascular or perineural invasion, < 12 lymph nodes, poor/un-differentiation, T4, or positive margins. Overall survival has been estimated for patients < 50 years using the Kaplan-Meier method and Cox multivariable analyses. Of the 81,066 stage II individuals who had a colectomy, 6,093 were < 50 years old. Of these, 2,669 individuals were HR. Risk status and age were the most significant multivariable predictors of aCTX. Young HR and NR cancer patients received aCXT more often than older patients with no demonstrable survival benefit. It requires further consideration in order to avoid the real risks of over-treatment in this growing population.